Pyxis Oncology, Inc.
PYXS
$1.34
$0.021.52%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -62.64% | -64.75% | -4.80% | 39.17% | 40.15% |
Total Depreciation and Amortization | -18.74% | -15.25% | 54.75% | 118.47% | 163.47% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 177.32% | 141.27% | 122.34% | -66.80% | -58.68% |
Change in Net Operating Assets | 18.35% | 125.20% | -1.36% | -74.38% | -232.33% |
Cash from Operations | -30.41% | 7.87% | 18.44% | 26.37% | 25.41% |
Capital Expenditure | 100.00% | 100.00% | 96.48% | 97.24% | 97.67% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -99.98% | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 817.07% | 251.38% | 108.01% | 93.01% | 92.99% |
Cash from Investing | 3,508.50% | 277.31% | 107.78% | 92.92% | 98.67% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -83.90% | -85.16% | 954.53% | 959.45% | 847.79% |
Repurchase of Common Stock | -1,028.65% | -1,100.62% | -1,673.03% | 25.70% | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -97.15% | -97.14% | 900.61% | 895.15% | 836.63% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -1,640.41% | 39.39% | 105.78% | 98.55% | 99.58% |